Group 1: Market Analysis - The Shanghai Composite Index is currently facing a resistance level at 3418 points and a support level at 3174 points, with the index closing at 3376 points on June 4, 2025, just 42 points away from the resistance level [5][6] - If the index effectively breaks above the 3418 points resistance, it may signal a shift from a long-term sideways trading range to an upward trend, with the 3418 points level becoming a strong support [5][6] - The index has attempted to break the 3418 points resistance five times since October 8, 2024, but has not succeeded, indicating significant market indecision [6] Group 2: Consumer Trends - During the Dragon Boat Festival, domestic tourism saw 119 million trips, a year-on-year increase of 5.7%, while tourism revenue reached 42.73 billion yuan, growing by 5.9% [9][10] - The average spending per person for domestic travel was 359.08 yuan, a slight decrease of 2.11% compared to the same period last year [9] - Short-distance and surrounding travel dominated, with nearly 50% of travelers opting for nearby destinations, and family trips being a significant trend due to the coinciding Children's Day [10][11] Group 3: Economic Indicators - The People's Bank of China announced a 1 trillion yuan reverse repurchase operation, indicating ongoing liquidity support in the market [16] - The tax authority reported that the private economy's vitality has been improving, with a 3.6% year-on-year increase in sales revenue for the private sector in the first four months of 2025, outpacing the overall growth of national enterprises [17][18] - The European Central Bank lowered interest rates by 25 basis points, reflecting a continued accommodative monetary policy stance in response to economic conditions [21]

[Table_Reportdate] 2025年06月05日 [table_stockTrend] -28% -16% -5% 7% 19% 31% 42% 24-06 24-09 24-12 25-03 25-06 申万行业指数:社会服务(0746) 沪深300 [相关研究 table_product] 1.旅游市场火热，出行半径扩大—— 五一消费数据点评 [Table_NewTitle 端午旅游]增速放缓 ——端午消费数据点评 [table_main] 投资要点： [table_invest] 标配 [证券分析师 Table_Authors] 任晓帆 S0630522070001 rxf@longone.com.cn 行业简评 一、评级说明 | | 评级 | 说明 | | --- | --- | --- | | 市场指数评级 | 看多 | 未来 6 个月内沪深 300 指数上升幅度达到或超过 20% | | | 看平 | 未来 6 个月内沪深 300 指数波动幅度在-20%—20%之间 | | | 看空 | 未来 6 个月内沪深 300 指数下跌幅度达到或超过 20% | | 行业指数评级 | 超配 | ...

总 量 研 究 [Table_Reportdate] 2025年06月05日 [若有效上破 Table_NewTitle] 3418点压力位，指数或有进 一步盘升动能 策 略 研 究 [证券分析师 Table_Authors] 王洋 S0630513040002 wangyang@longone.com.cn [相关研究 Table_Report] 1.《波浪里前行 上证指数目前或处 于黎明的曙光中》 2.《上证指数或酝酿反弹动能——技 术分析上证指数系列》 3.《上证指数短线或有反弹需求—— 技术分析上证指数简评》 4.《上证指数或有进一步震荡盘升动 能——技术分析上证指数简评》 5.《上证指数短线技术条件明显修 复，回落空间小上涨空间大——技术 分析上证指数简评》 6.《证券板块技术条件有所向好，上 涨空间大回落空间小——技术分析 行业板块简评》 7.《保险板块或已走出下降趋势，上 涨空间大回落空间小——技术分析 行业板块简评》 [table_main] 投资要点 ➢ 核心观点：上证指数目前上有3418点一线的压力，下有3174点一线的支撑，目前尚未有效 突破。近日指数正趋近3418点一线的压力位，压力位 ...

[Table_Reportdate] 2025年06月05日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250605 [table_summary] 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 ➢ 1.英伟达Q1数据中心业务成绩亮眼，美限制EDA龙头对华提供服务——电子行业周报 2025/5/26-2025/6/1 ➢ 2.关注陆家嘴论坛政策发布预期带来的市场情绪催化——非银金融行业周报（20250526- 20250601） ➢ 1.四部门组织开展人力资源服务业与制造业融合发展试点工作 ➢ 2.美国ISM服务业PMI大幅回落，跌至50荣枯线以下 ...

[Table_Reportdate] 2025年06月04日 ➢ 1.创新药密集上市，关注后续医保谈判————医药生物行业周报（2025/05/26- 2025/06/01） ➢ 2.供给端扰动背景下，关注相关化工板块配置机会——基础化工行业周报（2025/05/26- 2025/06/01） ➢ 3.白酒持续筑底，重视新消费趋势——食品饮料行业周报（2025/5/26-2025/6/1） ➢ 4.轨交设备板块业绩改善，关注后续铁路固定资产投资进展——机械设备行业周报 （20250526-20250601） 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 联系人： 花雨欣 hyx@longone.com.cn [晨会纪要 Table_NewTitle] 20250604 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的 ...

[Table_Reportdate] 2025年06月03日 超配 [证券分析师 Table_Authors] 姚星辰 S0630523010001 yxc@longone.com.cn 联系人 吴康辉 wkh@longone.com.cn -30% -20% -10% 0% 10% 20% 2024-05 2024-07 2024-09 2024-11 2025-01 2025-03 2025-05 食品饮料(申万) 沪深300 [相关研究 table_product] 1.龙头酒企保持战略定力，期待需求 修 复 — — 食 品 饮 料 行 业 周 报 （2025/5/19-2025/5/25） 2.产能加快调整，2025年奶价有望企 稳——乳制品行业深度报告 3.白酒底部区间，大众品关注高成长 性赛道 — — 食 品 饮 料 行 业 周 报 （2025/5/12-2025/5/18） [Table_NewTitle 白酒持续筑底 ] ，重视新消费趋势 ——食品饮料行业周报（2025/5/26-2025/6/1） [table_main] 投资要点： 行 业 研 究 证券研究报告 HTTP://WWW.LO ...

Investment Rating - The report provides a standard investment rating for the basic chemical industry, indicating a cautious outlook due to recent market fluctuations and supply chain disruptions [1]. Core Insights - Japan's Mitsui Chemicals is exiting the NF3 business, which may enhance China's competitiveness in electronic specialty gases, with potential market share expansion [4][10]. - The chlorantraniliprole incident has caused supply disruptions, potentially boosting the market for pesticides and intermediates, with a shift towards high-efficiency, low-toxicity products [4][12]. - The report suggests focusing on key sub-sectors such as integrated refining and petrochemical chains, refrigerant industry leaders, and domestic alternative materials [4][14]. Summary by Sections 1. Industry News and Event Commentary - Mitsui Chemicals' exit from the NF3 business is attributed to rising competition and costs, indicating that Chinese manufacturers may fill the gap and increase exports [10][11]. - The chlorantraniliprole incident is expected to accelerate market consolidation, benefiting companies with technological advantages and regulatory compliance [12][13]. 2. Chemical Sector Weekly Performance - For the week of May 26 to May 30, the Shanghai Composite Index fell by 1.08%, while the Shenwan Petroleum and Petrochemical Index rose by 0.40%, outperforming the market by 1.48 percentage points [15][18]. - The basic chemical index decreased by 0.66%, ranking 23rd among all Shenwan primary industries [15][18]. 3. Key Product Price and Spread Performance - Notable price increases included potassium chloride (up 5.66%) and paraxylene (up 4.94%), while hydrochloric acid saw a significant drop of 28.00% [27][28]. - The price spread for carbon black increased by 31.13%, indicating a tightening supply situation [29][30].

[Table_Reportdate] 2025年06月03日 [table_invest] 标配 行 业 周 报 [证券分析师 Table_Authors] 吴骏燕S0630517120001 wjyan@longone.com.cn 证券分析师 谢建斌S0630522020001 xjb@longone.com.cn 证券分析师 张晶磊S0630524090001 zjlei@longone.com.cn 联系人 花雨欣 [Table_NewTitle 供给端扰动背景下，关注相关化工板块 ] 配置机会 ——基础化工行业周报（2025/05/26-2025/06/01） [table_main] 投资要点： ➢ 本周重点新闻跟踪 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 hyx@longone.com.cn [table_stockTrend] -30% -20% -10% -1% 9% 18% 28% 24-05 24-08 24-11 25-02 申万行业指数:基础化工(0722) 沪深300 [相关研究 table_product] 1.日本 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].